Applicant, as named in the Orange Book

Merck Sharp Dohme

Merck & Co Inc · NYSE: MRK

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Prevymis on 30 Aug 2031. 4 products with live protection, 2 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Prevymis NDA 209939 · 2 strengths letermovir	letermovir	30 Aug 2031 exclusivity	exclusivity
Prevymis NDA 209940 · 2 strengths letermovir	letermovir	28 Feb 2033 patent	patent
Belsomra NDA 204569 · 4 strengths suvorexant	suvorexant	29 May 2033 patent	patent
Welireg NDA 215383 belzutifan	belzutifan	30 Jun 2042 patent	patent

Stromectol · Generic approved · ANDA 216808, E5 PharmaApproved 9 Mar 2026Detected 25 Oct 2026
Stromectol · Generic approved · ANDA 218509, Ajanta Pharma LtdApproved 7 Apr 2026Detected 25 Oct 2026
Belsomra · Generic tentatively approved · ANDA 219386, Hetero Labs Ltd Unit IiiTentative approval 22 Dec 2025Detected 25 Oct 2026
Noxafil · Generic approved · ANDA 213331, ApotexApproved 29 Jun 2026Detected 25 Oct 2026
Pepcid Preservative Free In Plastic Container · Generic approved · ANDA 217432, LupinApproved 12 May 2026Detected 25 Oct 2026
Stromectol · Generic approved · ANDA 216863, Zydus LifesciencesApproved 26 Feb 2026Detected 25 Oct 2026
Welireg · Exclusivity expires within 90 days I-931Exclusivity expires 14 Dec 2026Detected 24 Oct 2026

Products without listed protection (2)

Drug	Ingredient	Earliest generic entry	Basis
Stromectol NDA 050742 ivermectin	ivermectin	open now no listed protection	no listed protection
Temodar NDA 022277 temozolomide	temozolomide	open now no listed protection	no listed protection